[Aspergillus in airway material : Ignore or treat?]

Area of Science:

• Mycology
• Pulmonology
• Infectious Diseases

Background:

• Fungi of the genus Aspergillus are widespread, with humans inhaling spores daily.
• Aspergillus-associated pulmonary diseases develop under specific host conditions, not from casual exposure.
• These diseases range from allergic conditions like hypersensitivity pneumonitis to infections such as invasive aspergillosis (IA) and chronic pulmonary aspergillosis (CPA).

Purpose of the Study:

• To outline the spectrum of Aspergillus-associated pulmonary diseases.
• To discuss diagnostic challenges and methods for Aspergillus infections.
• To highlight treatment strategies for different forms of aspergillosis.

Main Methods:

• Review of clinical presentations and diagnostic approaches for Aspergillus-related lung diseases.
• Discussion of immunological methods (e.g., IgG antibodies, galactomannan) versus definitive tissue identification.
• Analysis of treatment outcomes for acute invasive aspergillosis (IA/SIA) and chronic pulmonary aspergillosis (CPA).

Main Results:

• Diagnosis requires more than identifying Aspergillus in sputum; lung tissue culture/histopathology is the gold standard.
• Immunological tests are often used clinically to guide antifungal therapy decisions.
• Acute IA/SIA have high mortality and need immediate treatment; CPA often requires combined antifungal and surgical approaches for eradication.

Conclusions:

• Host immunity significantly influences the type and development of Aspergillus-induced lung diseases.
• Accurate diagnosis, utilizing both direct detection and immunological markers, is crucial for effective management.
• Treatment strategies must be tailored to the specific type of aspergillosis, with invasive forms requiring urgent intervention and CPA often needing multimodal therapy.